Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new test reveal the immune cells that beat hepatitis c?

NCT ID NCT01534728

Knowledge-focused Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study aims to develop a new laboratory technique to detect specific immune cells (called CD8 T cells) that target the hepatitis C virus (HCV). Researchers will use blood samples from people infected with HCV genotypes 1 or 4 to test and refine this technique. The goal is to better understand how the immune system clears the virus, which could lead to improved diagnostics and future vaccine development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tetramer technology for detecting HCV-specific T cells
What this could lead to
If successful, this could lead to better diagnostic tools for hepatitis C and inform vaccine design by identifying protective immune cells.
What could go wrong
This is an early-stage study focused on developing and testing a laboratory technique, not a treatment. The technology may not prove accurate or practical in larger, diverse populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

40 people

The number who actually took part.

Start date

Feb 2012

Finished

Mar 2014

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Chronic HCV Patients

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects * Age between 18 and 60 years * Signed Consent Form * Patient affiliated to social security * Infection with HCV genotype 1 or 4 : infection defined by the presence of HCV antibodies and HCV RNA in plasma allowing a measure of the circulating viral load, or resolved infection as defined by the presence of antibodies HCV, normal transaminases and negative HCV RNA measured by PCR (two consecutive tests) * Normal ECG in the judgment of the investigator * Venous access allowing a leukapheresis * Review hematologic allowing the realization of a leukapheresis to investigator assessment. Exclusion Criteria: * Patients being treated for HCV * HBV infection defined by the presence of HBsAg (serology already known, test not done specifically for research) * HIV infection defined by the detection of HIV antibodies (serology already known, test not done specifically for research) * Patients with cirrhosis * Patients addicted to narcotics use * Patients with excessive alcohol consumption (more than 3 units per day) * Pregnancy * Contraindications to leukapheresis * History of vasculitis related or unrelated to HCV * A person deprived of liberty by judicial or administrative decision.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C

Contacts and locations

Locations

  • Cochin Hospital

    Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.